Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, et al.
The Lancet (2020) Vol. 397, Iss. 10269, pp. 99-111
Open Access | Times Cited: 4698

Showing 1-25 of 4698 citing articles:

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 5, pp. 403-416
Open Access | Times Cited: 6978
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
David S. Khoury, Deborah Cromer, Arnold Reynaldi, et al.
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1205-1211
Open Access | Times Cited: 3729
A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance
Kathryn Skivington, Lynsay Matthews, Sharon Simpson, et al.
BMJ (2021), pp. n2061-n2061
Open Access | Times Cited: 3193
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Jamie Lopez Bernal, Nick Andrews, Charlotte Gower, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 7, pp. 585-594
Open Access | Times Cited: 2900
Features, Evaluation and Treatment Coronavirus (COVID-19)
Marco Cascella, Michael Rajnik, Arturo Cuomo, et al.
StatPearls (2020)
Closed Access | Times Cited: 2796
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
Nick Andrews, Julia Stowe, Freja Kirsebom, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 16, pp. 1532-1546
Open Access | Times Cited: 2091
Adaptive immunity to SARS-CoV-2 and COVID-19
Alessandro Sette, Shane Crotty
Cell (2021) Vol. 184, Iss. 4, pp. 861-880
Open Access | Times Cited: 1749
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, et al.
The Lancet (2021) Vol. 397, Iss. 10275, pp. 671-681
Open Access | Times Cited: 1715
Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA
Sahil Loomba, Alexandre de Figueiredo, Simon J. Piatek, et al.
Nature Human Behaviour (2021) Vol. 5, Iss. 3, pp. 337-348
Open Access | Times Cited: 1516
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Shabir A. Madhi, Vicky L. Baillie, Clare Cutland, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 20, pp. 1885-1898
Open Access | Times Cited: 1270
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
Jamie Lopez Bernal, Nick Andrews, Charlotte Gower, et al.
BMJ (2021), pp. n1088-n1088
Open Access | Times Cited: 1202
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, et al.
The Lancet (2021) Vol. 397, Iss. 10277, pp. 881-891
Open Access | Times Cited: 1143
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Shuo Feng, Daniel J. Phillips, Thomas White, et al.
Nature Medicine (2021) Vol. 27, Iss. 11, pp. 2032-2040
Open Access | Times Cited: 1104
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
Daming Zhou, Wanwisa Dejnirattisai, Piyada Supasa, et al.
Cell (2021) Vol. 184, Iss. 9, pp. 2348-2361.e6
Open Access | Times Cited: 1099
Therapeutic peptides: current applications and future directions
Lei Wang, Nanxi Wang, Wenping Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 1083
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
John S. Tregoning, Katie E. Flight, Sophie L. Higham, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 10, pp. 626-636
Open Access | Times Cited: 1031
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Peter B. Gilbert, David C. Montefiori, Adrian B. McDermott, et al.
Science (2022) Vol. 375, Iss. 6576, pp. 43-50
Open Access | Times Cited: 1020
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
Cristina Menni, Kerstin Kläser, Anna May, et al.
The Lancet Infectious Diseases (2021) Vol. 21, Iss. 7, pp. 939-949
Open Access | Times Cited: 986
The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 976
COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries
Julio S. Solís Arce, Shana S. Warren, Niccoló Meriggi, et al.
Nature Medicine (2021) Vol. 27, Iss. 8, pp. 1385-1394
Open Access | Times Cited: 956
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
Marie Scully, Deepak Singh, Robert Lown, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 23, pp. 2202-2211
Open Access | Times Cited: 918
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Noam Barda, Noa Dagan, Yatir Ben‐Shlomo, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 12, pp. 1078-1090
Open Access | Times Cited: 909
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
Mine Durusu Tanrıöver, Levent Doğanay, Murat Akova, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 213-222
Open Access | Times Cited: 877
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
Markus Hoffmann, Nadine Krüger, Sebastian Schulz, et al.
Cell (2021) Vol. 185, Iss. 3, pp. 447-456.e11
Open Access | Times Cited: 869
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
Alejandro Jara, Eduardo A. Undurraga, M. Cecilia Gonzalez Corcia, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 10, pp. 875-884
Open Access | Times Cited: 860
Page 1 - Next Page

Scroll to top